Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth.
Brain. C C; Hindmarsh. P C PC; Pringle. P J PJ; Brook. C G CG
Key Findings
- Continuous subcutaneous infusion of GHRH (1-29)NH2 increased GH secretion in children with partial GH insufficiency.
- Growth velocity improved after 3 and 6 months of therapy.
- No desensitization of the GH response was observed during the treatment period.
Practical Outcomes
- For DIY biohackers, the results show that GHRH can boost GH, but the study used a continuous pump in children, which isn’t a practical or approved method for healthy adults. It suggests potential efficacy but more research is needed to develop safe, user‑friendly dosing regimens for longevity or performance goals.
Summary
A study gave kids with mild growth hormone problems a tiny pump that constantly delivered a peptide called GHRH (sermorelin) under the skin. Over three to six months, their hormone levels went up and they grew faster, with no sign that the body got used to the peptide.
Abstract
It has previously been shown that an 8-day continuous subcutaneous infusion of GHRH (1-29)NH2 in adult males augments growth hormone (GH) secretion with no evidence of desensitization of the response. The present report details the results of treatment with continuous subcutaneous infusions of GHRH (1-29)NH2 in eight children aged 6-9 years with partial GH insufficiency. All the children showed augmentation of GH secretion and an increase in growth velocity after 3 and 6 months of therapy.
Study Information
pubmed
1989
1989-01-01T00:00:00.000Z
10.1111/j.1651-2227.1989.tb17180.x
6
25